Beneficial Effects of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Use With Control-IQ Technology in Type 2 Diabetes.

Autor: Beck, Roy W., Levy, Carol J., Kudva, Yogish C., Pandit, Keta, Blevins, Thomas, Raghinaru, Dan, Pinsker, Jordan E.
Předmět:
Zdroj: Clinical Diabetes; Fall2024, Vol. 42 Issue 4, p547-549, 3p
Abstrakt: The article explores the effects of GLP-1 receptor agonist therapy on insulin doses and outcomes in individuals using AID systems for diabetes management. Topics include the increasing use of GLP-1 receptor agonists in conjunction with insulin therapy in type 2 diabetes, the findings from a clinical trial analyzing the impact of Control-IQ technology on blood glucose levels and insulin dosages, and the unexpected reduction in total daily insulin requirements.
Databáze: Complementary Index